BioSpace News Archive

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the quarter ended June 30, 2020 and provided a business update.

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of single-port robotic surgical technologies, announces financial results for the three and six months ended June 30, 2020.

AbbVie (NYSE: ABBV) today announced the publication of results from the Phase 3 VIALE-A clinical study in patients with AML in the New England Journal of Medicine (NEJM). T

Cipher Pharmaceuticals Inc. (TSX: CPH) (“Cipher” or the “Company”) announced today that it has filed, and the Toronto Stock Exchange (the “TSX”) has accepted, a Notice of Intention to Make a Normal Course Issuer Bid (the “Notice”).

Golden Helix has secured its reputation as a global leader in Next-Generation Sequencing solutions for over two decades. , they have been included in the esteemed Inc. 5000 list of rapidly growing American companies.

Seres Therapeutics, Inc., a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease, announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock, at a public offering price of $21.50 per share, before underwriting discounts and commissions.

QBiotics Group Limited, a life sciences company developing novel anticancer and wound healing pharmaceuticals, is pleased to announce that it has entered into an agreement with MSD, to evaluate use of its lead molecule tigilanol tiglate, in combination with Keytruda® in patients with unresectable melanoma.

TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported financial results for the second quarter ended June 30, 2020. Recent Highlights Reported revenue of $3.5 million for the second quarter of 2020, increasing 6% over the second quarter of 2019

Patients taking VILTEPSO showed an increase in dystrophin expression to an average of 5.9% of normal after 20-24 weeks of treatment.

--Sustained progress across clinical development programs spanning liver, retinal and metabolic diseases and cancer-- --Aldafermin continues to advance toward late-stage clinical development in non-alcoholic steatohepatitis (NASH) with ongoing Phase 2b ALPINE 2/3 and ALPINE 4 clinical studies-- --Initiated Phase 2 CATALINA study of NGM621, a complement C3 inhibitory antibody to treat patients with geographic atrophy (GA)-- --$312.1 million in cash, cash equivalents and marketable